Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Xenon Pharmaceuticals Inc is a biotechnology business based in the US. Xenon Pharmaceuticals shares (XENE) are listed on the NASDAQ and all prices are listed in US Dollars. Xenon Pharmaceuticals employs 123 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$17.86|
|52-week range||$9.32 - $21.94|
|50-day moving average||$17.41|
|200-day moving average||$18.27|
|Wall St. target price||$27.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.52|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-10)||2.35%|
|1 month (2021-08-19)||9.04%|
|3 months (2021-06-18)||-1.05%|
|6 months (2021-03-19)||-5.55%|
|1 year (2020-09-18)||56.12%|
|2 years (2019-09-19)||93.50%|
|3 years (2018-09-19)||33.78%|
|5 years (2016-09-19)||125.22%|
|Revenue TTM||$18.3 million|
|Gross profit TTM||$-18,357,000|
|Return on assets TTM||-15.76%|
|Return on equity TTM||-26.46%|
|Market capitalisation||$717.6 million|
TTM: trailing 12 months
There are currently 530,641 Xenon Pharmaceuticals shares held short by investors – that's known as Xenon Pharmaceuticals's "short interest". This figure is 20.4% down from 666,486 last month.
There are a few different ways that this level of interest in shorting Xenon Pharmaceuticals shares can be evaluated.
Xenon Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Xenon Pharmaceuticals shares currently shorted divided by the average quantity of Xenon Pharmaceuticals shares traded daily (recently around 148223.74301676). Xenon Pharmaceuticals's SIR currently stands at 3.58. In other words for every 100,000 Xenon Pharmaceuticals shares traded daily on the market, roughly 3580 shares are currently held short.
However Xenon Pharmaceuticals's short interest can also be evaluated against the total number of Xenon Pharmaceuticals shares, or, against the total number of tradable Xenon Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xenon Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Xenon Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0182% of the tradable shares (for every 100,000 tradable Xenon Pharmaceuticals shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Xenon Pharmaceuticals.
Find out more about how you can short Xenon Pharmaceuticals stock.
We're not expecting Xenon Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Xenon Pharmaceuticals's shares have ranged in value from as little as $9.32 up to $21.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenon Pharmaceuticals's is 1.3614. This would suggest that Xenon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Xenon Pharmaceuticals Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1. 6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
Everything we know about the Volcon IPO, plus information on how to buy in.
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
Everything we know about the FGI Industries IPO, plus information on how to buy in.
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.